CTLA4 and cancer: When bound to its ligands CD80 or CD86 on the surface of various immune cells including B cells, monocytes and antigen-presenting cells, such as macrophages and dendritic cells, CTLA-4 downregulates immune responses preventing the immune system from killing cancer cells.